Detailed information for compound 143558

Basic information

Technical information
  • TDR Targets ID: 143558
  • Name: 11-amino-2,6-dimethyl-3,4-dihydro-2H-indolo[2 ,3-b]quinolin-1-one
  • MW: 279.336 | Formula: C17H17N3O
  • H donors: 1 H acceptors: 2 LogP: 3.18 Rotable bonds: 0
    Rule of 5 violations (Lipinski): 1
  • SMILES: CC1CCc2c(C1=O)c(N)c1c(n2)n(c2c1cccc2)C
  • InChi: 1S/C17H17N3O/c1-9-7-8-11-14(16(9)21)15(18)13-10-5-3-4-6-12(10)20(2)17(13)19-11/h3-6,9H,7-8H2,1-2H3,(H2,18,19)
  • InChiKey: NWCDOCLEZPSZBM-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • 11-azanyl-2,6-dimethyl-3,4-dihydro-2H-indolo[2,3-b]quinolin-1-one
  • 11-amino-2,6-dimethyl-3,4-dihydro-2H-quinolino[2,3-b]indol-1-one

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Rattus norvegicus GABA-A receptor; anion channel Starlite/ChEMBL No references

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Echinococcus granulosus glycine receptor subunit alpha 1 GABA-A receptor; anion channel   467 aa 430 aa 32.3 %
Loa Loa (eye worm) nicotinic acetylcholine receptor alpha subunit GABA-A receptor; anion channel   467 aa 379 aa 19.3 %
Onchocerca volvulus Large subunit GTPase 1 homolog GABA-A receptor; anion channel   467 aa 496 aa 26.0 %
Onchocerca volvulus GABA-A receptor; anion channel   467 aa 468 aa 28.6 %
Brugia malayi Neurotransmitter-gated ion-channel ligand binding domain containing protein GABA-A receptor; anion channel   467 aa 375 aa 21.9 %
Onchocerca volvulus GABA-A receptor; anion channel   467 aa 435 aa 29.7 %
Onchocerca volvulus Gamma-aminobutyric acid receptor subunit beta homolog GABA-A receptor; anion channel   467 aa 433 aa 34.6 %
Onchocerca volvulus GABA-A receptor; anion channel   467 aa 454 aa 30.4 %
Echinococcus granulosus glycine receptor subunit beta GABA-A receptor; anion channel   467 aa 439 aa 29.6 %
Echinococcus multilocularis glycine receptor subunit beta GABA-A receptor; anion channel   467 aa 478 aa 28.7 %
Echinococcus multilocularis glycine receptor subunit alpha 1 GABA-A receptor; anion channel   467 aa 430 aa 32.3 %
Onchocerca volvulus GABA-A receptor; anion channel   467 aa 447 aa 25.7 %
Loa Loa (eye worm) hypothetical protein GABA-A receptor; anion channel   467 aa 494 aa 25.5 %
Onchocerca volvulus Eukaryotic initiation factor 4A-III homolog GABA-A receptor; anion channel   467 aa 453 aa 26.9 %
Onchocerca volvulus GABA-A receptor; anion channel   467 aa 434 aa 26.7 %
Onchocerca volvulus Acetylcholine receptor subunit alpha-type homolog GABA-A receptor; anion channel   467 aa 418 aa 19.6 %
Loa Loa (eye worm) hypothetical protein GABA-A receptor; anion channel   467 aa 461 aa 27.8 %
Brugia malayi Cation transporter family protein GABA-A receptor; anion channel   467 aa 453 aa 28.5 %
Schistosoma mansoni Cys-loop ligand gated ion channel subunit GABA-A receptor; anion channel   467 aa 479 aa 29.2 %
Brugia malayi nicotinic acetylcholine receptor alpha subunit, putative GABA-A receptor; anion channel   467 aa 384 aa 19.5 %
Brugia malayi Neurotransmitter-gated ion-channel ligand binding domain containing protein GABA-A receptor; anion channel   467 aa 454 aa 29.5 %
Loa Loa (eye worm) hypothetical protein GABA-A receptor; anion channel   467 aa 441 aa 33.8 %
Loa Loa (eye worm) hypothetical protein GABA-A receptor; anion channel   467 aa 446 aa 29.1 %
Onchocerca volvulus GABA-A receptor; anion channel   467 aa 446 aa 28.0 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Echinococcus multilocularis acetylcholinesterase 0.0139 1 1
Leishmania major hypothetical protein, conserved 0.0084 0 0.5
Toxoplasma gondii kringle domain-containing protein 0.0084 0 0.5
Loa Loa (eye worm) hypothetical protein 0.0139 1 1
Onchocerca volvulus 0.0084 0 0.5
Loa Loa (eye worm) hypothetical protein 0.0139 1 1
Echinococcus granulosus carboxylesterase 5A 0.0139 1 1
Echinococcus granulosus acetylcholinesterase 0.0139 1 1
Schistosoma mansoni family S9 non-peptidase homologue (S09 family) 0.0139 1 1
Loa Loa (eye worm) acetylcholinesterase 1 0.0139 1 1
Plasmodium falciparum cysteine repeat modular protein 1 0.0084 0 0.5
Echinococcus multilocularis carboxylesterase 5A 0.0139 1 1
Trypanosoma cruzi hypothetical protein, conserved 0.0084 0 0.5
Echinococcus multilocularis acetylcholinesterase 0.0139 1 1
Plasmodium vivax cysteine repeat modular protein 1, putative 0.0084 0 0.5
Brugia malayi Carboxylesterase family protein 0.0139 1 1
Loa Loa (eye worm) carboxylesterase 0.0139 1 1
Echinococcus granulosus acetylcholinesterase 0.0139 1 1

Activities

Activity type Activity value Assay description Source Reference
Change (functional) = 0 % Punished responding phase in Geller-Seifter test was determined at 1 hr post-dose of 2.5 mg/Kg p.o. ChEMBL. No reference
Change (functional) = 0 % Percent change in variable interval unpunished responding phase (VI) after administration of 20 mg/Kg oral dose in rat Geller-Seifter test. ChEMBL. No reference
Change (functional) = 19 % Punished responding phase in Geller-Seifter test was determined at 1 hr post-dose of 5 mg/Kg p.o. ChEMBL. No reference
Change (functional) = 22 % Punished responding phase in Geller-Seifter test was determined at 2 hr post-dose of 10 mg/Kg p.o. ChEMBL. No reference
Change (functional) = 36 % Punished responding phase in Geller-Seifter test was determined at 2 hr post-dose of 20 mg/Kg p.o. ChEMBL. No reference
Change (functional) = 43 % Punished responding phase in Geller-Seifter test was determined at 1 hr post-dose of 10 mg/Kg p.o. ChEMBL. No reference
Change (functional) = 52 % Punished responding phase in Geller-Seifter test was determined at 1 hr post-dose of 20 mg/Kg p.o. ChEMBL. No reference
Change (functional) = 52 % Percent change in punished responding phase (FR) after administration of 20 mg/Kg oral dose in rat Geller-Seifter test ChEMBL. No reference
Change (functional) = 62 % Punished responding phase in Geller-Seifter test was determined at 2 hr post-dose of 50 mg/Kg p.o. ChEMBL. No reference
Change (functional) = 137 % Punished responding phase in Geller-Seifter test was determined at 1 hr post-dose of 100 mg/Kg p.o. ChEMBL. No reference
Change (functional) = 141 % Punished responding phase in Geller-Seifter test was determined at 2 hr post-dose of 100 mg/Kg p.o. ChEMBL. No reference
Change (functional) = 146 % Punished responding phase in Geller-Seifter test was determined at 1 hr post-dose of 50 mg/Kg p.o. ChEMBL. No reference
IC50 (binding) = 0.95 uM Inhibition of [35S]-TBPS binding to Gamma-aminobutyric-acid A (GABA-A) receptor of rat brain in the presence of 5 uM GABA ChEMBL. No reference
IC50 (binding) = 0.95 uM In vitro inhibition of [35S]-t-butyl-bicyclophosphorothionate (TBPS) binding to Gamma-aminobutyric-acid A (GABA-A) receptor ChEMBL. No reference
IC50 (binding) = 0.95 uM Inhibition of [35S]-TBPS binding to Gamma-aminobutyric-acid A (GABA-A) receptor of rat brain in the presence of 5 uM GABA ChEMBL. No reference
IC50 (binding) = 0.95 uM In vitro inhibition of [35S]-t-butyl-bicyclophosphorothionate (TBPS) binding to Gamma-aminobutyric-acid A (GABA-A) receptor ChEMBL. No reference
IC50 (binding) > 100 uM Displacement of [3H]-Flunitrazepam from rat cerebral cortex ChEMBL. No reference
IC50 (binding) > 100 uM Inhibition of [3H]-flunitrazepam binding to GABA-A receptor ChEMBL. No reference
IC50 (binding) > 100 uM Displacement of [3H]-Flunitrazepam from rat cerebral cortex ChEMBL. No reference
IC50 (binding) > 100 uM Inhibition of [3H]-flunitrazepam binding to GABA-A receptor ChEMBL. No reference
MED (functional) = 5 mg kg-1 Minimum effective peroral dose of the compound in Geller-Seifter paradigm ChEMBL. No reference
Nr/N (functional) = 0 Number of animals responding out of those tested (Nr/N) in Geller-Seifter test was determined at 1 hr post-dose of 2.5 mg/Kg p.o. (Animals tested 6) ChEMBL. No reference
Nr/N (functional) = 5 Number of animals responding out of those tested (Nr/N) in Geller-Seifter test was determined at 1 hr post-dose of 10 mg/Kg p.o. (Animals tested 6) ChEMBL. No reference
Nr/N (functional) = 5 Number of animals responding out of those tested (Nr/N) in Geller-Seifter test was determined at 1 hr post-dose of 20 mg/Kg p.o. (Animals tested 6) ChEMBL. No reference
Nr/N (functional) = 5 Number of animals responding out of those tested (Nr/N) in Geller-Seifter test was determined at 1 hr post-dose of 50 mg/Kg p.o. (Animals tested 6) ChEMBL. No reference
Nr/N (functional) = 5 Number of animals responding to the above phases out of 6 tested, expressed as Nr/N ChEMBL. No reference
Nr/N (functional) = 6 Number of animals responding out of those tested (Nr/N) in Geller-Seifter test was determined at 1 hr post-dose of 100 mg/Kg p.o. (Animals tested 6) ChEMBL. No reference
Nr/N (functional) = 6 Number of animals responding out of those tested (Nr/N) in Geller-Seifter test was determined at 2 hr post-dose of 20 mg/Kg p.o. (Animals tested 6) ChEMBL. No reference
Nr/N (functional) = 6 Number of animals responding out of those tested (Nr/N) in Geller-Seifter test was determined at 2 hr post-dose of 50 mg/Kg p.o. (Animals tested 6) ChEMBL. No reference
Nr/N (functional) = 6 Number of animals responding out of those tested (Nr/N) in Geller-Seifter test was determined at 2 hr post-dose of 100 mg/Kg p.o. (Animals tested 6) ChEMBL. No reference
Nr/N (functional) = 7 Number of animals responding out of those tested (Nr/N) in Geller-Seifter test was determined at 2 hr post-dose of 10 mg/Kg p.o. (Animals tested 14) ChEMBL. No reference
Nr/N (functional) = 8 Number of animals responding out of those tested (Nr/N) in Geller-Seifter test was determined at 1 hr post-dose of 5 mg/Kg p.o. (Animals tested 14) ChEMBL. No reference

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

No literature references available for this target.

If you have references for this compound, please enter them in a user comment (below) or Contact us.